Listed

Takeda Pharmaceutical Co Ltd: Form 20-F for the period ended Mar 31, 2021

Filed with the SEC on Jun 29, 2021 and accepted by EDGAR at Jun 29, 2021, 06:06 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2020-04-01 to 2021-03-31JPY 3.20tnifrs-full:Revenue
Cost of revenue12 months2020-04-01 to 2021-03-31JPY 994.31bnifrs-full:CostOfSales
Operating income12 months2020-04-01 to 2021-03-31JPY 509.27bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2020-04-01 to 2021-03-31−JPY 9.94bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2020-04-01 to 2021-03-31JPY 376.00bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2020-04-01 to 2021-03-31JPY 238.96ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2020-04-01 to 2021-03-31JPY 240.72ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2020-04-01 to 2021-03-31JPY 1.01tnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2020-04-01 to 2021-03-31JPY 111.21bnifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2021-03-31JPY 966.22bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-03-31JPY 2.71tnifrs-full:CurrentAssets
Total assetsAt period end2021-03-31JPY 12.91tnifrs-full:Assets
Current liabilitiesAt period end2021-03-31JPY 1.77tnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2021-03-31JPY 7.74tnifrs-full:Liabilities
Shareholders' equityAt period end2021-03-31JPY 5.17tnifrs-full:EquityAttributableToOwnersOfParent

Source: SEC EDGAR, the filing index for accession 0001395064-21-000140. Last ingested by Listed: Nov 5, 2026, 16:17 ET. Listed shows no prices and gives no investment advice.